Related Experiment Video
Updated: Nov 12, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
[Cancer treatment and risk of heart failure]
Dorra Mbarek1, Mariana Mirabel2
1Unité de cardio-oncologie, AP-HP, Hôpital européen Georges-Pompidou, Paris, France.
Abstract:
Cancer treatment and risk of heart failure. As new advancements in oncology have radically changed the prognosis in millions of cancer patients, these have become at high risk of multiple cardiovascular complications. Heart failure is likely the most common cardiovascular side effect of cancer therapies. Definition of heart failure induced by cancer treatment resides in the reduction of left ventricular ejection fraction under 50%. Biomarkers as the reduction of left ventricular longitudinal function or troponin raise are associated with the advent of heart failure. Risk of cardiotoxicity includes traditional cardiovascular risk factors, lifestyle and cancer treatment(s). In addition to anthracyclins, which may lead to persistent heart failure, target therapies, radiotherapy and immune checkpoint inhibitors may be responsible for cardio-toxicity. Early screening of drug related heart failure may lead to medical treatment thus enabling the continuation of cancer cardiotoxic drugs when no other alternative is available. Cardio-oncology, a new discipline, guides decision making in these complex patients.
Related Concept Videos
Heart Failure I: Introduction
Heart Failure VII: Nursing Interventions
Heart Failure VI: Adjunct Therapies
Treatment Resistant Cancers
Heart Failure IV: Classification and Diagnostic Evaluation
Cancer Survival Analysis

